Author:
Greenspan S. L.,Vujevich K. T.,Brufsky A.,Lembersky B. C.,van Londen G. J.,Jankowitz R. C.,Puhalla S. L.,Rastogi P.,Perera S.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism
Reference34 articles.
1. Becker T, Lipscombe L, Narod S, Simmons C, Anderson GM, Rochon PA (2012) Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer. J Am Geriatr Soc 60(9):1761–1767. doi: 10.1111/j.1532-5415.2012.04107.x
2. Bauer M, Bryce J, Hadji P (2012) Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer. Breast Cancer (Dove Medical Press) 4:91–101. doi: 10.2147/bctt.s29432
3. Hadji P (2010) Guidelines for osteoprotection in breast cancer patients on an aromatase inhibitor. Breast Care (Basel, Switzerland) 5(5):290–296. doi: 10.1159/000321426
4. Greenspan SL, Brufsky A, Lembersky BC, Bhattacharya R, Vujevich KT, Perera S et al (2008) Risedronate prevents bone loss in breast cancer survivors: a 2 year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 26(16):2644–2652. doi: 10.1200/JCO.2007.15.2967
5. Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C et al (2012) Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118(5):1192–1201. doi: 10.1002/cncr.26313
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献